Overview: nmCRPR

• "Prostate cancer is the most common cancer in men, accounting for 19% of new cancer cases." According to the American Cancer Society, in 2019, nearly 174,650 new cases of prostate cancer were diagnosed in the United States, and about 31,620 American men died from prostate cancer.
• Not all cases can be cured with localized treatment options. In fact, twenty to thirty percent of men experience "a disease recurrence requiring systemic hormonal treatment with androgen-deprivation therapies (ADTs)."
• ADTs are medical or surgical treatments that lower testosterone. These treatments include treatments to "suppress or block the production or action of male hormones called androgens, of which testosterone is the primary androgen. While ADT is often effective, in certain men, prostate cancer adapts and can progress."
•  Castration-resistant prostate cancer (CRPC), the disease progression despite ADT treatment, is treated with nonmetastatic CRPC (nmCRPC), which works essentially on delaying metastasis while maintaining the patient survival quality.
• Traditionally, the main treatment options were first-generation androgen receptor inhibitors (FGARIs) and active surveillance.
• In 2018, the FDA approved drugs, the second-generation ARis (SGARIs) such as apalutamide and enzalutamide.
• In 2019, "darolutamide became the newest available oral androgen receptor inhibitor approved by the FDA for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC) patients."

Summary of Our Early Findings Relevant to The Goals

• Our preliminary research highlighted the available treatment options for nmCRPR.
• The initial hour of the research didn't cover every part of the requested information, so we haven't confirmed yet if we can find all the requested and suggested data.
• Our recommendations are based on our findings in early research.
• Please select one or more of the options provided in the proposed scoping section below.